CXCL10 and non-small cell lung carcinoma: Cheng et al. studied the influence of lipid metabolic pathway mutations in non-small cell lung carcinoma (NSCLC) tissue samples and reported that higher mutations in the lipid metabolism pathway in these cancers are associated with improved immunogenicity as seen with increased infiltration of activated memory CD4+ T cells, γδ T cells, or CD8+ T cells as well as M0 and M1 macrophages and also upregulated the inflammation mediating gene profile (e.g., IFNγ, CXCL9, and CXCL10) [37].